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BACKGROUND: To date, no good marker for screening or disease monitoring of endometrial cancer (EC) is available. The aims of this
study were to investigate HE4 gene, protein expression and serum HE4 (sHE4) levels in a panel of ECs and normal endometria (NEs)
and to correlate sHE4 with patient clinicopathological characteristics and prognosis.
METHODS: Using quantitative real-time PCR we tested 46 ECs and 20 NEs for HE4 gene expression. Protein expression was analysed
by immunohistochemistry on tissue microarrays in 153 ECs and 33 NEs. Pre-operative serum samples from 138 EC and 76 NE
patients were analysed with HE4–EIA assay. Association between sHE4 and patient clinicopathological characteristics or outcome
was evaluated.
RESULTS: Protein and HE4 gene were significantly upregulated in EC tissues and sera, compared with controls. High sHE4 levels were
significantly associated with worse EC clinical characteristics. By univariate survival analysis, high sHE4 levels significantly correlated
with decreased overall survival, progression-free survival and disease-free survival, retaining their independent prognostic value on the
poorly differentiated EC cohort.
CONCLUSION: We demonstrate, for the first time, that high sHE4 levels correlates with an aggressive EC phenotype and may constitute
an independent prognostic factor for poorly differentiated-ECs. Determination of sHE4 could be clinically useful in identifying high-risk
EC patients for a more aggressive adjuvant therapy.
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Endometrial carcinoma (EC) is the most common gynaeco-
logical malignancy in the Western world. (Sherman, 2000; Amant
et al, 2005). Most EC patients have oestrogen-related tumours,
well-differentiated, endometrioid in histology and, consequently,
with good prognosis (Type I ECs). In contrast, Type II ECs include
non-oestrogen-related poorly differentiated endometrioid, serous
papillary and clear-cells ECs, which being aggressive and meta-
static at presentation, often recur despite aggressive clinical
interventions (Bokhman, 1983). Unfortunately, to date, no good
marker for EC screening, early diagnosis or disease monitoring is
available. In this regard, CA125 serum determination is often used
in clinical practice to monitor EC patients (Duk et al, 1986).
However, this marker appears to have limited utility in analysing
the effects of adjuvant therapy or in the prediction of tumour
recurrence. Endometrial carcinoma conventional prognostic
factors are tumour grade, International Federation of Gynecology
and Obstetrics (FIGO) staging and histological type (Bokhman,
1983; Cirisano et al, 1999, 2000; Creasman et al, 2001; Gemer et al,
2004), but they are insufficient to identify patients with poor
prognosis. The recent progress in molecular biology has identified
novel biological markers (Kohler et al, 1996; Risinger et al, 1998;
Maxwell et al, 2001; Morrison et al, 2006) representing important
alternative indicators of patients with biologically aggressive, high-
risk tumours, which may benefit from adjuvant therapies to
improve outcome (Greven et al, 2006; Randall et al, 2006).
Human epididymis protein HE4 (WFDC2) was first identified by
Kirchhoff et al (1991) and specifically localised to the epithelial
cells of the epididymal duct. More recently, HE4 expression has
been reported in a number of normal human tissues outside of the
male reproductive system, as well as in various types of human
carcinomas, including EC (Bingle et al, 2002; Galgano et al, 2006).
A recent paper of Moore et al (2008) demonstrated that HE4
preoperative serum levels discriminate EC patients from healthy
postmenopausal women, suggesting its promising value as
diagnostic serological marker to be used alone or in combination.
In the present report, we have analysed HE4 gene expression
levels by quantitative real-time PCR, whereas protein expression
was tested by immunohistochemistry on tissue microarrays in a
large cohort of EC patients. Furthermore, with the aim to confirm
HE4 potential utility in EC diagnosis, using a commercially
available ELISA assay, we have measured preoperative HE4 serum
levels in a large cohort of EC patients and in healthy controls. In
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saddition, we have compared HE4 serum levels with those of
CA125, the marker more often used in clinical practice. Finally,
we have investigated the correlation between HE4 serum levels and
either clinical factors or survival end points to determine its
potential prognostic significance. The univariate and multivariate
survival analyses were performed both on the entire cohort of EC
patients and on the poorly differentiated EC subgroup.
MATERIALS AND METHODS
Human tissue and serum samples and patient
characteristics
EC tissue samples were obtained from 153 patients treated at the
Division of Gynecologic Oncology of the University of Brescia,
Italy between September 2003 and July 2009. Moreover, samples
of normal endometria (NE) were collected from 33 age-matched
patients, undergoing surgery for benign pathologies. Preoperative
serum samples from 138 patients with EC and from 76 controls
(postmenopausal women without gynaecological pathologies) were
collected. The study was approved by the Institutional Review
Board and written informed consent was obtained from all the
patients enrolled. All pathology specimens were reviewed in our
institution and histological classification was performed according
to the WHO criteria, whereas pathological stage was determined in
accordance with the FIGO guidelines. Tumour tissues were
obtained from women undergoing total abdominal hysterectomy,
bilateral salpingo-oophorectomy and peritoneal washings for
cytology. Lymph node sampling or dissection was predominantly
performed in patients with tumours characterised by deep
myometrial invasion and/or high-grade or aggressive histology.
The presence of serious concomitant diseases, obesity and
advanced age were contraindications to full-surgical staging. None
of the patients had received preoperative chemotherapy or
radiation. Age, histological type, stage, grade, additional disease
(i.e., diabetes, obesity and blood pressure) and treatment
information were recorded in all cases. A group of 134 patients
was selected for survival analysis. Patients were followed up from
the date of surgery until death or the last observation (median
follow-up, 33.1 months, range 0.9–74.4 months). At the time of the
last follow-up, 107 patients (79.9%) were alive without evidence of
disease, 8 patients (6.0%) were alive with disease, 18 patients
(13.4%) were dead from disease and 1 died from other causes. For
subgroup survival analysis, 54 patients harbouring poorly
differentiated ECs were considered.
Total RNA extraction and quantitative real-time PCR
Tissue-sharp dissection, liquid nitrogen freezing and epithelial
purity checking of EC and NE samples were performed as
previously reported (Bignotti et al, 2006), as well as total RNA
extraction and reverse transcription. Quantitative real-time PCR
was performed in triplicate as previously reported (Bignotti et al,
2006), using the following Assay on Demand (Applied Biosystems,
Foster City, CA, USA): Hs00899484_m1 (WFDC2). Normal and EC
samples were analysed at the same time to avoid batch effects. Data
were normalised using glyceraldehyde-3-phosphate dehydrogenase
as internal control.
Tissue microarrays and immunohistochemistry
Tissue microarray blocks (TMAs) were created from 153 formalin-
fixed, paraffin-embedded EC and 33 NE tissues collected from the
Department of Surgical Pathology of the University of Brescia,
Italy. Tissue microarray blocks were constructed using an
automated tissue microarrayer (TMA Master, 3DHistech, Buda-
pest, Hungary). Representative areas were chosen for sampling
from haematoxylin and eosin (H&E) stained sections of selected
NE and EC cases of different histological subtypes. Four 0.6-mm
cores have been collected from different areas of each tumour
block in order to overcome tumour heterogeneity and the possible
loss of tissue because of cutting. Different TMAs were created for
low and advanced tumour grade, and normal tissue was included
in all TMAs to be used as control. Sections (4mm thick) were
cut from TMAs and H&E staining were used for confirmation
of tumour tissue. Tissue microarray sections were subjected
to antigen retrieval (15min in microwave oven at 750W in
sodium citrate buffer, pH 7.0), before application of the rabbit
polyclonal antibody to HE4 (1:40 dilution; Covance, Dedham,
MA, USA). The antibody was revealed with NovoLink polymer
(Novocastra Laboratories, Newcastle upon Tyne, UK), followed by
diaminobenzidine as chromogen; hematoxylin was used for
counterstaining. Immunoreactivity was evaluated by four inde-
pendent observers; cytoplasmic staining was graded for intensity
(0-negative, 1-weak, 2-moderate and 3-strong) and the percentage
of positive cells was scored as 0 (0%), 1 (1–10%), 2 (11–50%) and
3 (51–100%). A single scale with scores 0–9 was obtained by
multiplying the intensity and the percentage staining score, and a
total score was calculated by grouping score 0 in total score 0, 1–3
in total score 1, 4 and 6 in total score 2 and 9 in total score 3.
Digital images were resized by using Adobe Photoshop (Element
version) in order to have homogeneous cores (about 90% of the
full core is represented).
HE4 Immunoassay
All serum samples were collected, before any patient treatment,
frozen in liquid nitrogen within 2h of blood drawing and stored at
 801C. Serum HE4 levels were measured using HE4 EIA kit
(Fujirebio Diagnostics, Inc., Goteborg, Sweden), following manu-
facturer’s instruction. Normal and EC samples were analysed in
duplicate at the same time to avoid batch effects.
CA125 serum level measurements
Serum CA125 values were determined by the clinical laboratory at
the Spedali Civili di Brescia, Italy using the Architect CA125 II
chemiluminescent two step immunoassay kit (Abbott Diagnostics,
Abbott Park, IL, USA), following the manufacturer’s protocol.
Normal and EC samples were analysed at the same time to avoid
batch effects.
Statistical analysis
In all the analyses, HE4 gene expression has been considered on
log-scale. Differences in HE4 gene expression between ECs and
NEs were evaluated with t-test, whereas IHC values were tested
with the Wilcoxon rank sum test and Mann–Whitney U-test.
Differences in HE4 serum levels between the groups were
calculated using ANOVA. Spearman’s rank correlation was used
to estimate the degree of association between serum HE4 (sHE4)
and CA125 values, whereas Kendall’s coefficient was used to
estimate the degree of concordance between IHC and ELISA data.
Combination of markers was investigated comparing ROC curves,
based on the method proposed by DeLong et al (1988). Different
ROCs are built, based on predicted values for each sample derived
from logistic models, accounting for different combinations of
markers. Predicted values are computed using leave-one-out cross
validation. The association between HE4 serum levels and
clinicopathological parameters was investigated with ANOVA.
For survival analysis, three end points (cancer relapse, cancer
progression and death due to cancer) were used to calculate
disease-free survival (DFS), progression-free survival (PFS) and
overall survival (os), respectively. Disease-free survival was defined
as the time interval between the date of surgery and the date of
identification of disease recurrence, PFS was defined as the time
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sinterval between the date of surgery and the date of identification
of progressive disease (disease not treatable with curative intent)
and OS was defined as the time interval between the date of
surgery and the date of death. For all three end points, the last
date of follow-up was used for censored subjects. Survival models
were fitted using the Cox proportional hazard models, whereas
survival curves were drawn based on the Kaplan–Meier methods.
The effect of HE4 serum levels on prognosis was evaluated
by categorising the values in tertiles computed on the entire cohort
(low; medium; high). In all the analyses, a P-valueo0.05 was
considered significant. All the analyses were performed using R
(R Development Core Team, 2010).
RESULTS
HE4 gene expression by quantitative RT–PCR
Human epididymis protein HE4 gene expression was tested by qRT–
P C Ri n4 6E C s( 2 0p o o r l yd i f f e r e n t i a t e d (G3), 17 moderately differentiated
( G 2 )a n d9w e l ld i f f e r e n t i a t e d( G 1 ) )a n d2 0N E s .A ss h o w ni nF i g u r e1 ,
HE4 mRNA expression was significantly higher in EC compared with NE
patients (FC¼2.63, 95% CI: 1.78–3.88, Po0.0001).
HE4 protein expression by immunohistochemical staining
To analyse HE4 expression results at the protein level, immuno-
histochemistry for HE4 was carried out on 153 EC (53 G3,
60 G2 and 40 G1, including 119 endometrioid ECs and 34 non-
endometrioid ECs) and 33 NE (16 during proliferative phase and
17 during secretory phase) TMAs. As shown in Table 1, a positive
staining for HE4 was detected in 130 out of 153 (85.0%) ECs
and appeared to be moderate/strong (score 2/3) in 59.5% of
cases. Normal endometria tissues predominantly showed a weak
immunoreactivity, with presence of score 1 in 57.6% of cases.
Endometrial cancers showed markedly increased HE4 positivity as
compared with NEs (P¼0.03). As represented in Figure 2, HE4
staining in EC and NE samples appeared to be cytoplasmic and
restricted to the epithelial compartment, with no positivity in
adjacent stromal cells.
As displayed in Table 1, all G1 cases were positive and most of
them (31 out of 40, 77.5%) showed a cytoplasmic staining with
moderate/strong score. Most of G2 cases (53 out of 60, 88.3%) were
also found positive for HE4 and showed a moderate/strong
score in 65% of cases, whereas G3 tumours (32 out of 53, 60.4%)
were mainly scored negative/weak. Immunostaining of HE4 was
significantly greater in G1 and in G2 tumours compared with G3
ones (Po0.0001 and P¼0.0062, respectively). Moreover, immuno-
reactivity for HE4 was significantly stronger in endometrioid ECs
compared with non-endometrioid ECs (P¼0.016).
Serum HE4 levels
Serum samples were collected from 138 EC patients and 76 healthy
controls and tested with HE4 ELISA. Median, mean and range
values for each group are displayed in Figures 3A and B. As shown,
sHE4 levels were significantly higher in EC patients compared with
NEs (median ECs¼83pM, median NEs¼38pM,F C ¼2.33,
Po0.0001, 95% CI: 2.02–2.73), regardless of the FIGO stage
(NEs vs Stage I ECs, P¼0.004; NEs vs stage II, III or IV ECs,
Po0.0001) and differentiation grade (NEs vs G1, G2 or G3 ECs,
Po0.0001). Moreover, sHE4 levels in G1 ECs showed a significant
difference with G2 ECs (FC¼1.64, P¼0.0009, 95% CI: 1.22–2.20).
The comparisons between G2 ECs and G3 ECs and between G1 ECs
and G3 ECs were not significant (P¼0.240 and P¼0.066,
respectively). In addition, sHE4 levels were higher in patients with
advanced FIGO stages: I–II (mean 90) vs III–IV stages (mean
174), P¼0.014. Finally, sHE4 levels and IHC results showed a low
concordance in paired tumour samples (P¼0.18, W¼0.563).
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Figure 1 HE4 mRNA expression in endometrial carcinoma (EC)
compared with normal endometrial tissues (NE). The figure shows the
box plot of the relative quantification values in Log scale. As shown, HE4
mRNA expression was significantly higher in EC compared with NE
patients (Po0.0001).
Table 1 HE4 immunoreactivity in tissue microarrays of endometrial
carcinomas (ECs) and normal endometria (NEs)
HE4 protein expression
n
Score¼0
n (%)
Score¼1
n (%)
Score¼2
n (%)
Score¼3
n (%)
ECs 153 23 (15.0) 39 (25.5) 61 (39.9) 30 (19.6)
G1 40 0 (0.0) 9 (22.5) 16 (40.0) 15 (37.5)
G2 60 7 (11.7) 14 (23.3) 27 (45.0) 12 (20.0)
G3 53 16 (30.2) 16 (30.2) 18 (34.0) 3 (5.6)
NEs 33 2 (6.0) 19 (57.6) 12 (36.4) 0 (0.0)
Abbreviations: HE4¼human epididymis protein 4; EC¼endometrial carcinoma;
NE¼normal endometria.
Normal
G2 G3
200 micron
G1
Figure 2 Representative immunohistochemical staining for HE4 in tissue
microarrays of normal endometria (normal) and endometrial carcinomas
(G1, G2 and G3). Normal tissues show predominantly a weak
immunoreactivity for HE4 (mostly 1þ), whereas G1, G2 and G3
endometrial carcinomas are mainly scored 3þ,2 þ and 0/1þ,
respectively. Magnification:  100; scale bar length: 200micron.
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sComparison between HE4 and CA125 serum levels and
combination of the two markers
We analysed CA125 serum levels in 127 EC patients and in 71 NEs,
all tested with HE4 ELISA. Analysed CA125 median values were
11U (range 4–42), 12U (range 3–40), 20U (range 1–202) and
19U (range 4–853) for NEs, G1, G2 and G3 ECs, respectively.
Median values of CA125 were 15U (range 1–114), 15U (range
4–50), 39U (range 4–202) and 67U (range 18–853) for stage I,
stage II, stage III and stage IV ECs, respectively. The difference
between serum CA125 levels in NEs compared with all ECs was
statistically significant (median ECs¼18U, median NEs¼11U,
Po0.0001), whereas it was not significant when comparing NEs
with G1 ECs (P¼0.99), NEs with stage I ECs (P¼0.95) and NEs
with stage II ECs (P¼0.93). Logistic models were used to compare
the sensitivity of CA125 and HE4 markers for the differentiation of
ECs vs NEs at set specificities of approximately 90, 95 and 98%
(Table 2). HE4 showed a considerably higher sensitivity compared
with CA125 for detecting EC, considering all stages and all set
specificities. For instance, HE4 had a sensitivity of 67% at a
specificity of 95% compared with 30% for CA125. For stage I
cancers, HE4 exhibited a 39% improvement in sensitivity at a
specificity of 95% compared with CA125 alone (Table 2). As CA125
and HE4 serum levels were significantly correlated, but exhibited a
low Spearman’s rank coefficient (Po0.01, rs¼0.38), a combina-
tion of the two markers was analysed. The combination of CA125
and HE4 led to a further improvement in sensitivity, even if
limited, compared with HE4 alone, considering all set specificities
and all EC stages. Examining only stage I EC patients, there was no
gain in sensitivity when CA125 and HE4 were combined compared
with HE4 alone.
sHE4 levels and clinicopathological variables
The relationship between sHE4 levels and the clinicopathological
features of the 138 EC patients is shown in Table 3. Higher sHE4
levels were significantly associated with advanced age at diagnosis,
menopause, higher FIGO stage and grade, deeper myometrial
invasion, positive lymph nodes, presence of lymphovascular
invasion, cervical and adnexal involvement, positive peritoneal
cytology and administration of either chemotherapy or adjuvant
radiation therapy.
sHE4 levels and patient survival
As expected, known EC clinical prognostic factors such as FIGO
stage, histological type and lymph node involvement showed a
statistically significant association with OS, PFS and DFS in
univariate analyses (all Po0.05, data not shown), proving the
validity of the patient cohort recruited in this study. In addition, as
displayed in Figures 4A and B, respectively, higher HE4 serum
levels (high vs low HE4 tertiles) showed a significant association
with poor OS (P¼0.02) and shorter PFS (P¼0.03). Regarding DFS
(Figure 4C), medium vs low HE4 tertiles was significantly
correlated with decreased DFS (P¼0.04), whereas the difference
between high and low HE4 tertiles showed a marginal significance
(P¼0.06). FIGO stage, histological type, lymph node involvement
and HE4 serum levels were then included in a multivariate
analysis. Non-endometrioid EC histological subtype, along with
advanced FIGO stage, were identified as independent predictive
factors for poor OS (P¼0.01 and P¼0.04, respectively, Table 4A),
whereas sHE4 levels (medium vs low tertile) were shown to be
marginally significant as prognostic factor for shorter OS (P¼0.08,
Table 4A). Regarding PFS, only histological type and, marginally,
FIGO stages were of prognostic significance, whereas sHE4 levels
were not (Table 4A). Regarding DFS, neither clinical parameters
nor sHE4 levels were indicative of disease recurrence, even if
elevated sHE4 levels exhibited the highest trend toward signifi-
cance (P¼0.14 and P¼0.17, Table 4A). Then we performed a
further survival analysis in the subgroup of 54 patients harbouring
poorly differentiated ECs. The univariate model revealed that
patients with elevated sHE4 levels (high tertile) had a significant
poorer OS (P¼0.02, Figure 4D), shorter PFS (P¼0.02, Figure 4E)
and worse DFS (P¼0.01, Figure 4F) than patients with reduced
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Figure 3 Box plots showing serum HE4 (sHE4) levels in controls with normal endometrium (NE) and in endometrial cancer patients, represented
according to differentiation grade (A) and to FIGO stage (B).
Table 2 Tumour biomarker sensitivities among patients with endometrial cancer
Controls vs stage I EC: sensitivity (%) Controls vs all stages EC: sensitivity (%)
Marker 90% specificity (%) 95% specificity (%) 98% specificity (%) 90% specificity (%) 95% specificity (%) 98% specificity (%)
HE4 61 54 45 75 67 59
CA125 26 15 11 36 30 26
HE4+CA125 61 53 44 76 68 60
Abbreviations: CA125¼cancer antigen 125; EC¼endometrial carcinoma; HE4¼human epididymis protein 4.
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ssHE4 levels (low tertile). In multivariate analysis, sHE4 levels
retained its significance as an independent prognostic factor for
poor OS (P¼0.04), shorter PFS (P¼0.04) and decreased DFS
(P¼0.01) in the subgroup of patients with poorly differentiated
ECs (Table 4B).
DISCUSSION
Endometrial carcinoma (EC) is generally considered a malignancy
with favourable prognosis, because of the fact that the majority of
patients declare their disease early by postmenopausal bleeding
and therefore can be diagnosed at the first stage. However, an
accurate serum marker for screening and early diagnosis would
certainly be useful for those patients that may experience an
increased risk of developing EC, such as those with severe obesity
and diabetes, Lynch syndrome, PTEN gene defects or breast cancer
women on Tamoxifen. Moreover, several high-risk EC groups,
such as women with stages III–IV disease or even stage I patients
harbouring high-grade carcinomas, or deep myometrial invasion,
would benefit from a marker to give pre-operative indications, to
monitor the effects of adjuvant therapy and to predict early
tumour recurrence. Serum levels of CA125 are commonly used in
the clinic for these purposes, but exhibit a low sensitivity and
specificity (Sood et al, 1997; Powell et al, 2005). In the present
investigation, with the aim to fully characterise human epididymis
protein HE4 as a marker for EC, we have analysed its gene and
protein expression in tumour tissues, its secretion in the sera and,
finally, its prognostic value on a cohort of well-characterised EC
patients. In a previous microarray study, Huhtinen et al (2009)
examined HE4 gene expression in a limited number of EC samples,
finding no significant difference with NEs. Conversely, according
to our gene expression results, HE4 mRNA was significantly
upregulated in ECs compared with NEs. Moreover, we demon-
strated a significantly stronger HE4 immunohistochemical staining
in EC compared with NE tissues. HE4 immunostaining in NE
predominantly exhibits a weak score, whereas most EC samples
show moderate/strong scores. Those results are in agreement with
two previous reports regarding HE4 immunohistochemistry
performed on a limited number of EC and NE samples (Drapkin
et al, 2005; Galgano et al, 2006). Few recent studies have proposed
HE4, a candidate molecular marker for ovarian cancer, as a
promising serum marker for endometrial malignancies (Moore
et al, 2008; Huhtinen et al, 2009; Montagnana et al, 2009). Serum
CA125 and HE4 median values in EC and NE patients were
shown to be similar in our investigation compared with previous
studies, thus validating our patient cohort. In agreement with
Table 3 Clinical and pathological characteristics of 138 endometrial
cancer patients and their association to HE4 serum levels (pM)
Variable n HE4 median (IQR) P-value
Age at diagnosis (years)
o65 60 59 (51.5)
X65 78 96 (82.0) o0.01
FIGO stage
I+II 106 74 (56.0) o0.01
III+IV 32 112 (117.7)
WHO grading
Grade 1 25 64 (41.0)
Grade 2+3 113 89 (76.2) o0.01
Histology
Endometrioid 109 88 (79.0)
Non-endometrioid 29 70 (52.2) 0.68
Myometrial invasion
M0+M1 63 66 (42.5) o0.01
M2 75 98 (93.5)
Lymph node status
Negative 93 74 (53.0)
Positive 21 97 (108.0) 0.017
Unknown 24
Cervical involvement
Absent 91 74 (53.0)
Stromal involvement 26 141 (169.7) o0.01
Unknown 21
Adnexal involvement
Negative 121 82 (64.5)
Positive 17 95 (167.0) 0.04
Peritoneal cytology
Negative 121 82 (59.0)
Positive 12 126 (161.7) o0.01
Unknown 5
Lymphovascular invasion
Absent 60 68 (43.7) o0.01
Present 73 97 (88.7)
Unknown 5
Parity
Nulliparity 24 82 (66.0) 0.65
Pluriparity 112 84 (69.0)
Unknown 2
Body mass index
o25 46 89 (82.5)
X25 80 82 (75.0) 0.84
Unknown 12
Hypertension
Negative 58 80 (53.2)
Positive 78 88 (87.0) 0.09
Unknown 2
Diabetes
Negative 117 85 (58.2) 0.31
Positive 20 95 (92.0)
Unknown 1
Menopause
Negative 14 55 (57.2)
Positive 123 88 (68.2) 0.04
Unknown 1
Table 3 (Continued)
Variable n HE4 median (IQR) P-value
Smoking
Negative 98 82 (71.0)
Positive 26 77 (46.5) 0.33
Unknown 14
Radiotherapy
Negative 62 66 (44.0) 0.04
Positive 48 96 (68.0)
Unknown 28
Chemotherapy
Negative 62 66 (44.0)
Positive 17 120 (177.0) 0.02
Unknown 59
Abbreviations: FIGO¼International Federation of Gynecology and Obstetrics;
HE4¼human epididymis protein 4; IQR¼interquartile range; WHO¼World
Health Organisation.
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sMoore et al (2008) we observed significantly higher sHE4 levels in
EC patients when compared with healthy women. Considering all
EC stages, sHE4 sensitivity resulted to be higher than that of sCA125
in detecting cancer patients and, more importantly, we obtain the
same result when sHE4 is tested for the detection of stage I EC.
Interestingly, our study showed increased HE4 sensitivities at every
specificities compared with those reported in the literature (Moore
et al, 2008), regardless of the EC stage. Finally, the addition of HE4
to CA125 significantly raised the sensitivity compared with CA125
alone, either in the entire EC cohort (68 vs 30% at 95% specificity,
respectively), or in stage I ECs (53 vs 15% at 95% specificity,
respectively). Immunohistochemical staining data and sHE4 levels
showed a low concordance coefficient in paired tumour samples.
This discrepancy may be partially explained by the IHC semi-
quantitative scoring system and by the probable heterogeneity of the
tumour tissue. Furthermore, this finding suggests that HE4 ELISA,
that is a dynamic test to be performed at any time and offers precise
marker quantification in serum, should be preferred to tissue
immunostaining in EC clinical setting.
The HE4 higher sensitivity over CA125 in identifying stage I ECs
indicates its potential prognostic value in detecting early tumour
recurrence. There are limited evidence reporting sHE4 as a
predictive marker for recurrence in ovarian cancer (Havrilesky
et al, 2008; Anastasi et al, 2010), whereas to our knowledge, so
far no prognostic value of sHE4 levels in EC patients has been
investigated. Herein, for the first time we demonstrated the
significant association between elevated sHE4 levels and adverse
EC factors, which may suggest a relation between increased
tumour biological aggressiveness and HE4 release in EC. More-
over, our study is the first to correlate sHE4 levels with clinical
outcome in patients with EC. In univariate analysis on the entire
EC cohort, we found that higher sHE4 levels were significantly
more often observed in patients with poor OS, PFS and DFS. The
multivariate analysis showed histological type and staging as
independent prognostic factor for OS, whereas sHE4 levels did
not reach the statistical significance. We then decided to focus
our survival analysis on a high-risk subgroup of EC patients,
harbouring poorly differentiated ECs, characterised by highly
malignant cancers with poor prognosis (Bokhman, 1983). Re-
markably, this is the first investigation reporting higher sHE4
levels as the only independent prognostic factor for shortened PFS
and DFS in this selected group of patients. Regarding OS, sHE4
levels and histological types were independent prognostic factors,
with the former showing a higher hazard ratio compared with the
latter. Given these findings and the poor efficacy of current
treatment modalities, it seems that patients with poorly differ-
entiated ECs and high sHE4 levels could be managed more
aggressively, using contemporary therapeutic options, than those
with low sHE4 levels. However, these data should be confirmed
with additional studies on larger patient cohort before routine
sHE4 levels evaluation could be applied in the clinical setting.
Summarising, our results confirm that HE4 is an accurate and
sensitive serum marker for early detection of EC patients, exhibi-
ting a better diagnostic performance compared with CA125, which
is the marker conventionally used in EC management. In addition,
we demonstrated for the first time that high sHE4 levels may
identify patients harbouring a more aggressive EC phenotype and
may be an independent prognostic factor for OS, PFS and DFS in
poorly differentiated EC patients. Therefore, the evaluation of
sHE4 levels might be useful as an early, simple and highly efficient
tool to select high-risk EC patients who could benefit from a
tailored surgical (i.e., the extension of the lymph nodal dissection)
and adjuvant (i.e., the extension of radiotherapy fields, systemic
chemotherapy or both) therapy. Large prospective clinical studies
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potential of HE4 as a new tool for preoperative evaluation and
postoperative surveillance of EC patients.
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